Cargando…
Early Plasma Circulating Tumor DNA as a Potential Biomarker of Disease Recurrence in Non-metastatic Prostate Cancer
PURPOSE: In non-metastatic prostate cancer (nmPCa) setting, it is important to early identify the patients at risk of biochemical recurrence (BCR) for immediate postoperative intervention. Our study aimed to evaluate the potential clinical utility of circulating tumor DNA (ctDNA) for predicting dise...
Autores principales: | Fei, Xiaochen, Du, Xinxing, Gong, Yiming, Liu, Jiazhou, Fan, Liancheng, Wang, Jiayi, Wang, Yanqing, Zhu, Yinjie, Pan, Jiahua, Dong, Baijun, Xue, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372593/ https://www.ncbi.nlm.nih.gov/pubmed/36915250 http://dx.doi.org/10.4143/crt.2022.1557 |
Ejemplares similares
-
Early serial circulating tumor DNA sequencing predicts the efficacy of chemohormonal therapy in patients with metastatic hormone-sensitive prostate cancer
por: Du, Xinxing, et al.
Publicado: (2023) -
The prevalence and clinical implication of rare germline deleterious alterations in Chinese patients with prostate cancer: A real‐world multicenter study
por: Fei, Xiaochen, et al.
Publicado: (2021) -
Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations
por: Chi, Chenfei, et al.
Publicado: (2022) -
Engineering the MoS(2)/MXene Heterostructure for Precise and Noninvasive Diagnosis of Prostate Cancer with Clinical Specimens
por: Xie, Shaowei, et al.
Publicado: (2023) -
Transcriptomic signature defines two subtypes of locally advanced PCa with distinct neoadjuvant therapy benefits
por: Zhu, Yinjie, et al.
Publicado: (2023)